secwatch.observer — SEC 8-K summary
======================================

Issuer:     GridAI Technologies Corp. (GRDX)
CIK:        0001604191
Form:       8-K
Filed at:   2022-04-29T23:59:59+00:00
Accession:  0001140361-22-017051
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

First Wave BioPharma reports mixed Phase 2 trial for COVID-19 GI; cuts 20% of staff
--------------------------------------------------------------------------------

- Phase 2 RESERVOIR trial: FW-COV (niclosamide) safe but missed efficacy endpoint vs placebo on SARS-CoV-2 stool viral clearance.
- Austerity measures: 20% headcount reduction, closure of West Coast office and Langlade, France facility.
- Deferred certain payment obligations related to First Wave Bio, Inc. acquisition to conserve capital.
- Awaiting full RESERVOIR data in late May; advancing IBD programs (FW-UP, FW-UC, FW-CD) and adrulipase for EPI.
- David Hoffman appointed to Board, filling newly created seventh seat under merger agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604191/000114036122017051/0001140361-22-017051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604191/000114036122017051/brhc10036952_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-017051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer